(Q40218455)

18 September 2017

In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer (English)

1 reference

18 September 2017

1 reference

1 reference

Amy L Cooper

1

1 reference

18 September 2017

Victoria L Greenberg

2

1 reference

18 September 2017

Pamela S Lancaster

3

1 reference

18 September 2017

John R van Nagell

4

1 reference

18 September 2017

Stephen G Zimmer

5

1 reference

18 September 2017

Susan C Modesitt

6

1 reference

18 September 2017

language of work or name

English

0 references

publication date

16 October 2006

1 reference

18 September 2017

1 reference

18 September 2017

104

1 reference

18 September 2017

596-601

1 reference

18 September 2017

3

1 reference

18 September 2017

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.011

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.011

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.011

Histone deacetylase inhibitors in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.011

Histone deacetylases and cancer: causes and therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.011

Histone deacetylase inhibitors as new cancer drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.011

Histone deacetylase inhibitors in cancer treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.011

Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.011

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.011

Histone Deacetylase Inhibitors: From Chromatin Remodeling to Experimental Cancer Therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.011

Alteration of nucleosome structure as a mechanism of transcriptional regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.011

The fundamental role of epigenetic events in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.011

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.011

Histone deacetylase inhibitors promote apoptosis and differential cell cycle arrest in anaplastic thyroid cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.011

Histone deacetylase inhibitors: from target to clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.011

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.011

Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.011

Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.011

Novel biologically based therapies for Waldenstrom's macroglobulinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.011

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.011

Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.011

A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.011

Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.011

Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.011

Effects of sodium butyrate on growth, differentiation, and apoptosis in head and neck squamous carcinoma cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.011

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.011

Mechanisms of suberoylanilide hydroxamic acid inhibition of mammary cell growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.011

Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.011

The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.011

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.011

Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.011

Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.011

It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.011

10.1016/J.YGYNO.2006.09.011

7 January 2021

Identifiers

DOI

1 reference

18 September 2017

1 reference